Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Mai 2022 08:00 ET | Quelle: Sema4

Sema4 to Participate at Two Investor Conferences in June 2022

STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
04. Mai 2022 16:05 ET | Quelle: Sema4

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
02. Mai 2022 07:45 ET | Quelle: Sema4

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
26. April 2022 16:05 ET | Quelle: Sema4

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
22. Februar 2022 16:05 ET | Quelle: Sema4

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
22. Februar 2022 08:00 ET | Quelle: Sema4

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a...
03. November 2021 09:15 ET | Quelle: Sema4

Sema4 to Participate at Three Upcoming Investor Conferences in November

STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...
19. Oktober 2021 16:05 ET | Quelle: Sema4

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
13. September 2021 08:00 ET | Quelle: Sema4

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer

STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the appointment of Gustavo Stolovitzky, PhD, to the...
09. September 2021 08:00 ET | Quelle: Sema4

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the launch of Sema4 Elements™, a portfolio of...

Nächste Seite